Covance opens expanded Singapore lab
pharmafile | April 18, 2013 | News story | Research and Development | Covance
Covance has expanded its central laboratory facility in Singapore to meet growing demand for drug development services in the Asia-Pacific region.
The expansion is the latest in Covance’s continued investment in Singapore, and an important element of the strategic investment plans for the Asia-Pacific region that also includes recent growth in operations in China and Japan.
The laboratory, at approximately 2,700 square metres (29,000 square feet), is the largest of its kind in Singapore, providing clinical testing services to clients in Asia, including South Korea, Taiwan, Hong Kong, the Philippines, Australia, and India.
The expansion doubles the size of Covance’s genomics footprint in Singapore, while also adding capabilities in anatomic pathology and nutritional chemistry. Like Covance’s central laboratories in Indianapolis, Indiana; Geneva, Switzerland; Shanghai, China; and Tokyo, Japan, the Singapore facility also provides a full-service offering that includes chemistry, immunology, haematology, flow cytometry, genomics, anatomic pathology, and microbiology.
“For the last 13 years Covance has provided central laboratory testing services in Singapore, where we have seen increasing demand for efficient, high-quality clinical trial data and support,” said Jon Koch, Corporate VP and Global general manager, Central Laboratory Services, Covance.
“This expansion will help us better serve both our local and multinational customers’ R&D needs in key therapeutic areas like oncology and metabolic diseases while reflecting Covance’s continued commitment to the Asia-Pacific region.”
Deborah Keller, executive VP and Group president, R&D Laboratories at Covance added: “In addition to providing our clients in Asia the broadest access to clinical trial testing services, Covance’s facilities in the Asia-Pacific region also offer pre-clinical services together with a comprehensive range of clinical development services to support both regional and global trials.
“Being the only CRO with the expertise to develop a molecule from discovery through all pre-clinical and clinical milestones makes Covance a preferred provider for companies wishing to develop drug candidates in Asia and around the globe.”
Related Content
M&A activity drives record year for pharma outsourcing deals
A drastic increase pharma industry in M&A activity has propelled the value of pharmaceutical outsourcing …
LabCorp buys Covance for $6.1 billion
US medical diagnostics firm LabCorp has entered the drug development business via a $6.1 billion …
Contract research news in brief
TFS buys Italian CRO Dimensione Ricerca, AMRI closes a US facility plus business development updates …
